PDZK1 confers sensitivity to sunitinib in clear cell renal cell carcinoma by suppressing the PDGFR-β pathway.

Haibo WangLijie ZhangHua LiuYumeng Yang Wenxiu LuXuedi CaoXiaomei YangQiong QinRan SongDuiping FengSonglin WangTao Bai Junqi He

Published in: British journal of cancer (2024)

Our findings establish the miR-15b/PDZK1/PDGFR-β axis as a promising therapeutic target and a novel predictor for ccRCC patients' response to sunitinib treatment.

Keyphrases

end stage renal disease
renal cell carcinoma
ejection fraction
newly diagnosed
chronic kidney disease
metastatic renal cell carcinoma
peritoneal dialysis
patient reported outcomes
combination therapy
patient reported
replacement therapy